Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?

作者信息

Klotz Laurence

机构信息

Division of Urology, University of Toronto, and Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada.

出版信息

Curr Urol Rep. 2007 Sep;8(5):341-4. doi: 10.1007/s11934-007-0027-3.

DOI:10.1007/s11934-007-0027-3

PMID:17880830

Abstract

摘要

相似文献

Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?

Curr Urol Rep. 2007 Sep;8(5):341-4. doi: 10.1007/s11934-007-0027-3.

Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.

J Urol. 2008 Nov;180(5):1964-7; discussion 1967-8. doi: 10.1016/j.juro.2008.07.051. Epub 2008 Sep 17.

Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Eur Urol. 2009 Jun;55(6):1331. doi: 10.1016/j.eururo.2009.02.030. Epub 2009 Mar 6.

[Modern therapy of prostate cancer].

MMW Fortschr Med. 2014 Dec 15;156(21-22):71-3. doi: 10.1007/s15006-014-3815-y.

Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Eur Urol. 2009 Jun;55(6):1331-2. doi: 10.1016/j.eururo.2009.02.029. Epub 2009 Mar 6.

Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study.

Scand J Urol Nephrol. 2003;37(3):213-7. doi: 10.1080/00365590310008073.

Active surveillance for prostate cancer: has the time finally come?

J Clin Oncol. 2010 Jun 1;28(16):e265-6; author reply e267. doi: 10.1200/JCO.2010.28.1584. Epub 2010 Apr 20.

Further support for active surveillance in the management of low-volume, low-grade prostate cancer.

Eur Urol. 2010 Dec;58(6):836-7. doi: 10.1016/j.eururo.2010.09.003. Epub 2010 Sep 15.

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6.

Early prostate cancer.

Curr Probl Cancer. 2000 Jan-Feb;24(1):5-51. doi: 10.1016/s0147-0272(00)90007-2.

本文引用的文献

Active surveillance with selective delayed intervention for favorable risk prostate cancer.

Urol Oncol. 2006 Jan-Feb;24(1):46-50. doi: 10.1016/j.urolonc.2005.07.002.

Active surveillance for prostate cancer: for whom?

J Clin Oncol. 2005 Nov 10;23(32):8165-9. doi: 10.1200/JCO.2005.03.3134.

Prostate cancer and the Will Rogers phenomenon.

J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53. doi: 10.1093/jnci/dji248.

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7. doi: 10.1093/jnci/dji205.

Radical prostatectomy versus watchful waiting in early prostate cancer.

N Engl J Med. 2005 May 12;352(19):1977-84. doi: 10.1056/NEJMoa043739.

20-year outcomes following conservative management of clinically localized prostate cancer.

JAMA. 2005 May 4;293(17):2095-101. doi: 10.1001/jama.293.17.2095.

Cancer statistics, 2004.

CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8.

Active surveillance: towards a new paradigm in the management of early prostate cancer.

Lancet Oncol. 2004 Feb;5(2):101-6. doi: 10.1016/S1470-2045(04)01384-1.

Lead time associated with screening for prostate cancer.

Int J Cancer. 2004 Jan 1;108(1):122-9. doi: 10.1002/ijc.11554.

Prostate biopsy: how many cores are enough?

Urol Oncol. 2003 Mar-Apr;21(2):135-40. doi: 10.1016/s1078-1439(03)00006-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验